Advertisement


Pierfranco Conte, MD, on Early-Stage Triple-Negative Breast Cancer: Trial Update on Avelumab as Adjuvant Treatment

2024 ASCO Annual Meeting

Advertisement

Pierfranco Conte, MD, of the University of Padua, discusses phase III findings from the A-BRAVE trial, which was designed to evaluate the efficacy of avelumab, an anti–PD-L1 antibody, as adjuvant treatment for patients with early-stage triple-negative breast cancer who are at high risk (LBA500).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The A-BRAVE trial was an academic driven trial conducted in patients at high risk with early triple negative breast cancer. The purpose of the study was to improve the prognosis of these patients by selecting subgroup of patients at particularly high risk of relapse. In the study, we have randomized two strata of patients. One was patients who went to surgery upfront, and after surgery had a diagnosis of advanced stages of disease, high positivity, axillary lymph load, large tumor size. The second stratum were the patients who had received neoadjuvant chemotherapy and had surgery after neoadjuvant chemotherapy, still had invasive residual disease in the breast and/or in the axillary lymph nodes. The primary end points of the study were disease-free survival in the entire study population, and the disease-free survival in the post-neoadjuvant group, which included 82% of a total population. We didn't meet the primary end points, because we did observe a difference in favor of avelumab in disease-free survival, a 5% improvement at three years in disease-free survival in the whole population, and a 6% improvement in the post-neoadjuvant population. But this was not statistically significant, hazard ratio was 0.8, p-value 0.17. We did observe on the contrary, a statistically significant difference in overall survival in the entire study. Population at three years the advantage in overall survival for Avelumab was 8.5%, the hazard ratio 0.66, which means a 34% reduction in the risk of death, the p-value 0.035. We did also perform a postdoc exploratory analysis, try to understand why we are seeing a larger benefit in overall survival than disease-free survival, and the analysis was on distant disease-free survival. And again, we did observe a significant advantage for Avelumab, 7.5% improvement at three years in distant disease-free survival, hazard ratio 0.7, p-value 0.027. We do know that in many countries today standard of care for high-risk, early triple negative disease is neoadjuvant chemotherapy plus Pembrolizumab. So Pembrolizumab is given to all these patients before surgery, and also is continued after surgery, independently from the pathological response observed at surgery. And this is, as I said before, standard recommended by international and also national guidelines in Italy. There are aware still patients who do not receive Pembro if a neoadjuvant situation. Patients who have a smaller tumor size, clinically negative axillary lymph nodes, patients for whom physicians may, or might, have some concern about the tolerability of a treatment. So there are still patients who receive neoadjuvant chemotherapy without Pembro. Many of these patients fortunately receive a pathological [inaudible 00:04:00] response, but still some of them, 40 to 50%, have residual invasive disease, and they think that for these patients avelumab will be a good option. Highly effective in terms of distant disease-free survival, effective in terms of overall survival, and also tolerability was quite good. Now of course, this is the first presentation of the study, because the study was an event-driven study. We will follow up the patients longer, by sure. And there are many translational studies ongoing, because we have collected tumor samples, blood, plasma, and feces by all these patients. So, we will have a lot of translational research trying to understand who are the patients who benefit more, and who are the patients who unfortunately still relapse in spite of avelumab?

Related Videos

Pancreatic Cancer

Belinda Lee, MBBS, on Early-Stage Pancreatic Cancer: New Data on Guiding Adjuvant Chemotherapy

Belinda Lee, MBBS, of Peter MacCallum Cancer Centre, Northern Health, Walter & Eliza Hall Institute, Melbourne, discusses findings from the AGITG DYNAMIC-Pancreas trial on the potential role of serial circulating tumor DNA testing after upfront surgery to guide adjuvant chemotherapy for early-stage disease (Abstract 107).

Multiple Myeloma

Xavier P. Leleu, MD, PhD, on Multiple Myeloma: Update on Isatuximab, Lenalidomide, Dexamethasone, and Bortezomib

Xavier P. Leleu, MD, PhD, of France’s Université de Poitiers and Centre Hospitalier Universitaire de Poitiers, discusses phase III findings showing that isatuximab in combination with bortezomib, lenalidomide, and dexamethasone deepened responses and increased the rate of measurable residual disease negativity vs isatuximab with lenalidomide and dexamethasone in patients with newly diagnosed transplant-ineligible multiple myeloma (Abstract 7501).

Kidney Cancer

Toni K. Choueiri, MD, FASCO, on RCC: Biomarker Analysis From the CLEAR Trial

Toni K. Choueiri, MD, FASCO, of the Dana-Farber Cancer Institute, discusses phase III findings showing that, in patients with advanced renal cell carcinoma (RCC), the benefit of lenvatinib plus pembrolizumab vs sunitinib in overall response rate does not appear to be affected by such factors as geneexpression signatures for tumorinduced proliferation, PDL1 status, or the mutation status of RCC driver genes.

Lymphoma

Yasmin H. Karimi, MD, on Diffuse Large B-Cell Lymphoma: Update on Use of Epcoritamab Plus Chemotherapy

Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses data reaffirming the efficacy and feasibility of using epcoritamab plus R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin) in autologous stem cell transplant–eligible patients with diffuse large B-cell lymphoma. Response rates were reported to be high, and most patients proceeded to transplant (Abstract 7032).

Lymphoma

Peter Riedell, MD, on DLBCL: Expert Commentary on the DEB Study

Peter Riedell, MD, of The University of Chicago, discusses phase III results on the use of tucidinostat plus R-CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) with double expression of MYC and BCL2. The regimen appeared to improve event-free survival and complete response rates vs R-CHOP in the front-line setting. As this is an interim analysis, longer-term follow-up will be needed to better understand its impact, says Dr. Riedell.

Advertisement

Advertisement




Advertisement